A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumours With a KRAS G12C Mutation

Official Title

A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumours With a KRAS G12C Mutation

Summary:

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumours with a KRAS G12C mutation.

Trial Description

Primary Outcome:

  • Percentage of Participants With Adverse Events (AEs)
  • Percentage of Participants With Dose-Limiting Toxicities (DLTs)
  • Percentage of Participants With Changes From Baseline in Targeted Vital Signs
  • Percentage of Participants With Changes From Baseline in Targeted Clinical Laboratory Test Results
  • Percentage of Participants With Changes From Baseline in Targeted ECG Parameters
Secondary Outcome:
  • Plasma Concentration of GDC-6036
  • Objective Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST v1.1)
  • Duration of Response (DOR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST v1.1)
  • Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumours, Version 1.1 (RECIST v1.1)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society